Connect Biopharma (CNTB) Director Kleanthis Xanthopoulos Receives Award

What Happened

• Dr. Kleanthis Xanthopoulos, a director of Connect Biopharma Holdings Ltd (CNTB), was granted 5,000 ordinary shares on 2026-09-30. The Form 4 reports the acquisition as an award/grant (code A) at $0.00 per share (issued, not purchased).
• The shares were issued in lieu of a portion of his 2026 annual board cash retainer and are fully vested upon grant.

Key Details

• Transaction date: September 30, 2026; Filing date (Form 4): October 1, 2026 (appears timely).
• Grant: 5,000 ordinary shares; reported acquisition price: $0.00 (compensation issuance).
• Shares owned after transaction: not specified in the provided filing.
• Footnote: Under the company’s Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares instead of cash. The share count was calculated by dividing the applicable equity value by the average closing price of CNTB ordinary shares for the 30 days ending September 30, 2026, rounded down.
• No 10b5-1 plan, tax withholding, sale, or option exercise reported in this transaction.

Context

• This is a compensation grant to a non-employee director, which is common and generally reflects standard board pay rather than a personal purchase or sale signaling a view on the stock.
• Because the shares are fully vested on grant, there are no additional vesting conditions; however, grants do not necessarily indicate insider sentiment about future performance.